Immunosuppressive therapy for inflammatory bowel disease: Consensus by the Austrian Working Group on IBD;Immunsuppressiva in der therapie chronisch entzündlicher darmerkrankungen: Konsensus der Arbeitsgruppe Chronisch Entzündliche Darmerkrankungen der ÖGGH

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 9, 2004, Pages 1033-1045

  Reinisch, W ^a   Dejaco, C ^a   Knoflach, P ^b   Petritsch, W ^c   Vogelsang, H ^a   Tilg, Herbert ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL GRAZ   (Austria)

^d UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; STEROID; TACROLIMUS; THALIDOMIDE; TIOGUANINE;

ABORTION; ANUS FISTULA; APHERESIS; ARTICLE; CLINICAL TRIAL; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; ENTERITIS; FATIGUE; FETUS MALFORMATION; FEVER; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; ILEITIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; MUSCLE CRAMP; NEUROTOXICITY; PANCREATITIS; PARESTHESIA; POSTOPERATIVE CARE; PREGNANCY; PROGNOSIS; REMISSION; RESPIRATORY TRACT INFECTION; SKIN TOXICITY; SYSTEMATIC REVIEW; TREMOR; ULCERATIVE COLITIS; VOMITING;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INJECTIONS, INTRAMUSCULAR; MALE; METHOTREXATE; PLACEBOS; PREGNANCY; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SAFETY; TIME FACTORS;

EID: 8444245371     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813500     Document Type: Article

References (129)

1. Meuwissen SG et al. IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2000; 12: 13-18
2. Anstey A et al. Azathioprine - Clinical Pharmacology and current indications in autoimmune disorders. Bio Drugs 1998; 9: 33-47
3. Aarbakke J, Janka-Schaub G, Elion GB. Thiopurine biology and pharmacology. Trends Pharmacol Sci 1997; 18: 3-7
4. Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-1145
5. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40: 723-751
6. Lowry PW, Franklin CL, Weaver AL et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 656-664
7. Dewit O, Vanheuverzwyn R, Desager JP et al. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16: 79-85
8. Sandborn W, Sutherland L, Pearson D et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2003
9. Pearson DC, May GR, Fick G et al. Azathioprine for maintenance of remission in Crohn's disease (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2003
10. Present DH, Korelitz BI, Wisch N et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-987
11. Korelitz BI, Adler DJ, Mendelsohn RA et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 1993; 88: 1198-1205
12. Sandborn WJ, Tremaine WJ, Wolf DC et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117: 527-535
13. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118: 1018-1024
14. Markowitz J, Grancher K, Kohn N et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902
15. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 667-671
16. D'Haens G, Geboes K, Ponette E et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112: 1475-1481
17. Cuillerier E, Lemann M, Bouhnik Y et al. Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study. Eur J Gastroenterol Hepatol 2001; 13: 1291-1296
18. Nos P, Hinojosa J, Aguilera V et al. Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease. Gastroenterol Hepatol 2000; 23: 374-378
19. Korelitz B, Hanauer S, Rutgeerts P et al. Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology 1998; 114: G4141
20. Cosnes J, Larmurier I, Beaugerie L et al. Do immunosuppressants have any impact on the need for surgery in Crohn's disease? Gastroenterology 2003; 124: A-10
21. Lecomte T, Contou JF, Beugerie L et al. Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine. Dis Colon Rectum 2003; 46: 1469-1475
22. Dejaco C, Harrer M, Waldhoer T et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1113-1120
23. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608
24. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
25. Parsi MA, Achkar JP, Richardson S et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 707-713
26. Sands B, van Deventer S, Bernstein C et al. Long-term treatment of fistulizing Crohn's disease: Response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology 2002; 122: A81-A82
27. Stack WA, Williams D, Stevenson M et al. Immunosuppressive therapy for ulcerative colitis: results of a nation-wide survey among consultant physician members of the British Society of Gastroenterology. Aliment Pharmacol Ther 1999; 13: 569-575
28. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85: 717-722
29. George J, Present DH, Pou R et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 1711-1714
30. Ardizzone S, Molteni P, Imbesi V et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997; 25: 330-333
31. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-489
32. Khan ZH, Mayberry JF, Spiers N et al. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 2000; 62: 249-254
33. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627-630
34. Rosenberg JL, Wall AJ, Levin B et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 96-99
35. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1982; 284: 1291-1292
36. Sood A, Midha V, Sood N et al. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000; 19: 14-16
37. Orth T, Peters M, Schlaak JF et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000; 95: 1201-1207
38. Casson DH, Davies SE, Thomson MA et al. Low-dose intravenous azathioprine may be effective in the management of acute fulminant colitis complicating inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13: 891-895
39. Mahadevan U, Tremaine WJ, Johnson T et al. Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol 2000; 95: 3463-3468
40. Hawthorne AB, Logan RF, Hawkey CJ et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-22
41. Mate-Jimenez J, Hermida C, Cantero-Perona J et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 1227-1233
42. Kim PS, Zlatanic J, Korelitz BI et al. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol 1999; 94: 3254-3257
43. Fernandez-Banares F, Bertran X, Esteve-Comas M et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996; 91: 2498-2499
44. Van Gossum A, Schmit A, Adler M et al. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg 1997; 60: 197-200
45. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 1587-1592
46. Actis GC, Bresso F, Astegiano M et al. Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther 2001; 15: 1307-1311
47. Campbell S, Ghosh S. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome. Dig Liver Dis 2003; 35: 546-551
48. Domenech E, Garcia-Planella E, Bernal I et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 2061-2065
49. Bouhnik Y, Lemann M, Mary JY et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-219
50. Lemann M, Bouhnik Y, Colombel JF et al. Randomized, double-blind, placebo-controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn's disease (CD). Gastroenterology 122; 4: A23
51. Mantzaris G, Archavlis E, Christidou A et al. Does the efficacy of azathioprine wane as time on treatment goes by? Gastroenterology 2003; 124: A377
52. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002; 51: 143-146
53. Candy S, Wright J, Gerber M et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-678
54. Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994; 89: 362-366
55. Campbell S, Ghosh S. Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol 2001; 13: 1073-1076
56. Decaux G, Prospert F, Horsmans Y et al. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000; 135: 256-262
57. Thomas CW Jr, Lowry PW, Franklin CL et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003; 9: 237-245
58. Pearson DC, May GR, Fick GH et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-142
59. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 1998; 225: 92-99
60. Black AJ, McLeod HL, Capell HA et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-718
61. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713
62. Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-1030
63. Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 1995; 32: 114-116
64. Kaskas BA, Louis E, Hindorf U et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-142
65. Korelitz BI, Fuller SR, Warman JI et al. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 1999; 94: 424-426
66. Present DH, Meltzer SJ, Krumholz MP et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-649
67. Warman JL, Korelitz BI, Fleisher MR et al. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003; 37: 220-225
68. Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000; 45: 1810-1813
69. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000; 14: 1561-1565
70. McGovern DP, Travis SP, Duley J et al. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002; 122: 838-839
71. Lopez AJ, Schwab M, Dejaco C et al. The risk of re-induction after azthioprine (AZA)-induced pancreatitis is reduced under exposure to 6-thioguanine (6-TG) compared to 6-mercaptopurine (6-MP). Gut 2003; 35: A171
72. Dubinsky MC, Yang H, Hassard PV et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-915
73. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813-821
74. Russmann S, Zimmermann A, Krahenbuhl S et al. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001; 13: 287-290
75. Schröder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 2003; 98: 530-537
76. Feagan BG, Rochon J, Fedorak RN et al. Methotrexat for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-297
77. Oren R, Moshkowitz M, Odes S et al. Methotrexat in chronic active Crohn's disease: A double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 2203-2209
78. Arora S, Katkov W, Cooley J et al. Methotrexat in Crohn's disease: Result of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46: 1724-1729
79. Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000; 342: 1627-1632
80. Oren R, Arber N, Odes S et al. Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 1416-1421
81. Afadhli AAF, McDonald JWD, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software, 2003
82. Stange EF, Schreiber S, Fölsch UR et al. Diagnostik und Therapie des M. Crohn - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs-und Stoffwechselerkrankungen. Z Gastroenterol 2003; 41: 19-20
83. Sandborn WJ, Present DH, Isaacs KL et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125: 380-388
84. Sandborn WJ. Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol Belg 2001; 64: 201-204
85. Hawthorne AB. Ciclosporin and refractory colitis. Eur J Gastroenterol Hepatol 2003; 15: 239-244
86. Van Assche G, D'Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031
87. Hogenauer C, Wenzl HH, Hinterleitner TA et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 415-423
88. Kornbluth A. Is there still an argument for cyclosporine in the treatment of inflammatory bowel disease? Pro argument. Inflamm Bowel Dis 2003; 9: 194-197
89. Fellermann K, Luhmann D, Stange EF. Is there still a role for cyclosporine in the treatment of inflammatory boewl disease? Con argument. Inflamm Bowel Dis 2003; 9: 198-201
90. Dubinsky MC, Hassard PV, Seidman EG et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7: 181-189
91. Herrlinger KR, Deibert P, Schwab M et al. Remission maintenance by thioguanine in chronic active Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1459-1464
92. Derijks LJ, de Jong DJ, Gilissen LP et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003; 15: 63-67
93. Harrer M, Schwab M, Teml A et al. Open prospective study on 6-thioguanine for Crohn's disease intolerant or resistant to azathioprine and/or 6-mercaptopurine. Gastroenterology 2003; 122: T1663
94. Dubinsky MC, Vasiliauskas EA, Singh H et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298-303
95. Fickert P, Hinterleitner TA, Wenzl HH et al. Mycophenolate mofetil in patients with Crohn's disease. Am J Gastroenterol 1998; 93: 2529-2532
96. Neurath MF, Wanitschke R, Peters M et al. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999; 44: 625-628
97. Miehsler W, Reinisch W, Moser G et al. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol 2001; 96: 782-787
98. Orth T, Peters M, Schlaak JF et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000; 95: 1201-1207
99. Vasiliauskas EA, Kam LY, Abreu-Martin MT et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117: 1278-1287
100. Ehrenpreis ED, Kane SV, Cohen LB et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271-1277
101. Sabate JM, Villarejo J, Lemann M et al. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1117-1124
102. Shimoyama T, Sawada K, Hiwatashi N et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 2001; 16: 1-9
103. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003; 3: 81-92
104. Greenstein AJ, Gennuso R, Sachar DB et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985; 56: 2914-2921
105. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999; 26: 1705-1714
106. Palli D, Trallori G, Bagnoli S et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000; 119: 647-653
107. Lewis JD, Bilker WB, Brensinger C et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121: 1080-1087
108. Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated ted with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther 2001; 15: 1101-1108
109. Bebb JR, Logan RP. Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma? Aliment Pharmacol Ther 2001; 15: 1843-1849
110. Opelz G, Henderson R. Incidence of Non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516
111. Connell WR, Kamm MA, Dickson M et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-1252
112. Korelitz BI, Mirsky FJ, Fleisher MR et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999; 94: 3248-3253
113. Fraser AG, Orchard TR, Robinson EM et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002; 16: 1225-1232
114. Farrell RJ, Ang Y, Kileen P et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000; 47: 514-519
115. Dayharsh GA, Loftus EV Jr, Sandborn WJ et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122: 72-77
116. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118: 1018-1024
117. Nielsen OH, Andreasson B, Bondesen S et al. Pregnancy in Crohn's disease. Scand J Gastroenterol 1984; 19: 724-732
118. Nielsen OH, Andreasson B, Bondesen S et al. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18: 735-742
119. Alstead EM, Ritchie JK, Lennard-Jones JE et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99: 443-446
120. Alstead EM, Ritchie JK, Lennard-Jones JE et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99: 443-446
121. Francella A, Dyan A, Bodian C et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17
122. Huynh LA, Min DI. Outcomes of pregnancy and the management of immunosuppressive agents to minimize fetal risks in organ transplant patients. Ann Pharmacother 1994; 28: 1355-1357
123. Bertschinger P, Himmelmann A, Risti B et al. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol 1995; 90: 330
124. Armenti VT, Ahlswede KM, Ahlswede BA et al. National transplantation Pregnancy Registry - outcomes of pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1994; 57: 502-506
125. Armenti VT, McGrory CH, Cater JR et al. Pregnancy outcomes in female renal transplant recipients. Transplant Proc 1998; 30: 1732-1734
126. Data on file at Centocor Inc (Malvern, PA)
127. Donnenfeld AE, Pastuszak A, Noah JS et al. Methotrexate exposure prior to and during pregnancy. Teratology 1994; 49: 79-81
128. Kozlowski RD, Steinbrunner JV, MacKenzie AH et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88: 589-592
129. Petri M. Immunosuppressive drug use in pregnancy. Autoimmunity 2003; 36: 51-56